National and Kapodistrian University of Athens
Η χρήση της υπερηχοκαρδιογραφίας στη μελέτη της λειτουργικότητας των καρδιακών κοιλοτήτων σε ασθενείς με αιματολογική κακοήθεια
Abstract
dc:descriptionBackground: Advances in treatment including bone marrow transplantation (ΒΜΤ) have significantly contributed to the improvement in survival of patients with hematologic malignancies over the last decades. Bone marrow transplantation has been established as the treatment of choice in a variety of hematologic and lymphoid malignancies. Despite the significant improvement in survival rates, concerns have emerged regarding early and late cardiovascular dysfunction after BMT, attributed partly to the use of chemotherapy before BMT. Cancer therapeutics–related cardiac dysfunction is commonly defined as a decrease in left ventricular ejection fraction (LVEF) and is a common complication associated with increased incidence of heart failure and increased mortality. Thus, early detection of cardiotoxicity is of crucial importance to prevent irreversible cardiac dysfunction by closer monitoring, modification of therapy, and appropriate antiremodeling treatment. Echocardiography has a central role in the noninvasive evaluation of changes in cardiac function before initiation, during, and after treatment with potentially cardiotoxic agents. Cardiotoxicity is defined as a decrease in the LVEF of >10 percentage points, to a value <53% (normal reference value for two-dimensional (2D) echocardiography (2D Echo) by means of 2D echo. However, LVEF is a load-dependent parameter and establishes the diagnosis of cardiotoxicity in a relatively advanced stage, when impairment of heart function may be irreversible. Assessment of myocardial deformation by means of speckle tracking derived strain and strain rate is a less load-dependent and a sensitive method to detect subclinical ventricular dysfunction before LVEF is reduced in patients treated for various types of cancer. Myocardial deformation analysis has been used in the setting of anthracycline and trastuzumab-induced impairment of cardiac function but has not been applied after chemotherapy with conditioning regimens in patients scheduled for BMT. In our study, we aimed to detect the presence of early cardiac dysfunction after treatment with chemotherapy regimens in BMT patients by means of conventional and new echo techniques including speckle tracking and 3D echocardiography. We also assessed the prognostic value of various echo parameters and high sensitivity troponin for. the identification of abnormal LVEF and cardiotoxicity at the end of the follow-up after BMT. Methods: We prospectively enrolled 80 patients (mean age, 45±11 years; 44men) who underwent BMT. Diagnoses included non-Hodgkin’s lymphoma, acute myeloid leukemia, and chronic myeloid leukemia. Before conditioning chemotherapy, 90% of the patients had received treatment with anthracyclines. All patients had normal LVEF. Cardiac structure and function was assessed by means of : a) conventional and b) Tissue Doppler Imaging echo markers c) two dimensional deformation indices of both ventricles. Left ventricular global longitudinal strain (LVGLS) and strain rate at systole and early diastole (LVGLSR, LVGLSRE), subendocardial and subepicardial longitudinal strain, circumferential strain, left ventricular twist (LV twist), and right ventricular global longitudinal strain (RVGLS) and strain rate (RVGLSR) were measured by speckle-tracking, and d) three dimensional echocardiography for assessment of LVEF (3DLVEF) and right ventricular ejection fraction (3DRVEF). Abnormal LVEF was defined as <53% according to current quidelines. Studies were performed before (baseline) and 1, 3, 6, and 12 months after chemotherapy conditioning followed by BMT. In parallel with echo parameters values of high sensitivity troponins were also measured for detection of subclical myocardial damage. Results: Impaired LVGLS values were observed at 1 month after chemotherapy and at 3, 6, and 12 months compared with baseline.LVGLS: -20% ± 2.2% at baseline, -18.4% ± 2.1% at 1 month, -17.3% ± 2.2% at 3 months, -17.1% ± 2.1% at 6 months, and -17.1% ± 2.2% at 12 months; P = 0 .001). Early LVGLS changes were driven mostly by changes in subendocardial longitudinal strain: -22.5% ± 2.4% at baseline, -20.5% ± 2.3% at 1 month, -19.2% ± 2.3% at 3 months, -19.2% ± 2.4% at 6 months, and -19.1% ± 2.4% at 12 months; P = 0.001), whereas significant subepicardial longitudinal strain and LV twist changes were observed at 3 months after BMT. Compared with baseline, RVGLS was also impaired early after chemotherapy: -22.3% ± 2.6% at baseline, -20.5% ± 2.6% at 1 month, -20.2% ± 2.4% at 3 months, -20.1% ± 2.4% at 6 months and -20.1% ± 2.3% at 12 months; P = 0.02). Compared with baseline, LVEF was slightly reduced (P = 0.02) at the end of the follow-up. 3DLVEF: 58.4% ± 4.1% at baseline, 57.8% ± 4.2% at 1 month, 56.8% ± 4.3% at 3 months, 56.4% ± 4.4% at 6 months, 56% ± 4.2% at 12 months; P = 0.02, whereas 3DRVEF did not change over the follow-up period. At the end of the follow-up period 14 patients (17.5%) had abnormal 3DLVEF<53%. Among echocardiographic markers, LVGLS at 1 month had the strongest predictive value for abnormal LVEF (<53%) at 12 months (area under the curve 0.86; 95% CI, [0.76–0.96]). A cut off LVGLS value of -18.4% had sensitivity of 84.6% and specificity of 71.9% for the identification of abnormal LVEF at the end of follow-up. During a 20±4 months follow-up period for cardiac events, 3 patients (3,75%) were hospitalized for heart failure. High sensitivity troponin values were also elevated early from 1 month post BMT and remained increased during the whole follow-up period, however its prognostic value was smaller compared to LVGLS for the detection af abnormal LVEF at the end of the follow-up. Conclusions: Following chemotherapy for BMT, myocardial deformation analysis detects early subclinical biventricular dysfunction. Left ventricular dysfunction was evident from 1 month after BMT, mainly in the subendocardial layer, whereas subepicardial deformation indices and LV twist were also impaired at 3 months, suggesting progressive subclinical cardiac dysfunction that preceded small reductions in LVEF. Deterioration of cardiac function could be attributed to previous treatment with anthracyclines before the decision to perform BMT, combined with a cardiotoxic effect triggered by chemotherapy conditioning for BMT. Impaired LVGLS at 1 month had a predictive value for the identification of abnormal LVEF at the end of the follow-up period. Given the relatively younger age and the notable increase in the number of hematologic malignancy survivors after BMT in recent years, there is a need for specific approaches to minimize incidence of heart failure and long-term adverse cardiac events. Thus, study of longitudinal deformation could be applied early after BMT to detect clinically significant myocardial dysfunction and prevent adverse cardiac remodeling and cardiovascular events by appropriate treatment in BMT.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Makavos, George
- Μακαβός, Γεώργιος
Subjects
dc:subject × 16- Αιματολογικές κακοήθειες
- Υπερηχοκαρδιογραφία
- Τριδιάστατη υπερηχοκαρδιογραφία
- Υπερηχοκαρδιογραφία μυοκαρδιακής παραμόρφωσης
- Μεταμόσχευση μυελού των οστών
- Καρδιοτοξικότητα
- Hematologic malignancies
- Echocardiography
- Three dimensional echocardiography
- Myocardial deformation echocardiography
- Bone marrow transplantation
- Cardiotoxicity
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42948